KemPharm Analyst Ratings
KemPharm Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/17/2022 | 355.58% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
09/15/2022 | 355.58% | Canaccord Genuity | → $20 | Initiates Coverage On | → Buy |
08/17/2022 | 127.79% | HC Wainwright & Co. | $11 → $10 | Maintains | Buy |
01/31/2022 | 150.57% | HC Wainwright & Co. | $10 → $11 | Upgrades | Neutral → Buy |
04/09/2021 | 127.79% | HC Wainwright & Co. | $12 → $10 | Maintains | Neutral |
03/04/2021 | 173.35% | HC Wainwright & Co. | $24 → $12 | Downgrades | Buy → Neutral |
01/25/2021 | 537.81% | Roth Capital | → $28 | Initiates Coverage On | → Buy |
05/20/2020 | -65.83% | HC Wainwright & Co. | $2.5 → $1.5 | Reiterates | → Buy |
11/20/2019 | -43.05% | HC Wainwright & Co. | $3 → $2.5 | Reiterates | → Buy |
09/05/2019 | -76.08% | Roth Capital | $4.25 → $1.05 | Downgrades | Buy → Neutral |
06/19/2019 | -31.66% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
05/23/2018 | 287.24% | Janney Montgomery Scott | → $17 | Initiates Coverage On | → Buy |
02/26/2018 | 150.57% | Canaccord Genuity | $7 → $11 | Maintains | Buy |
日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
---|---|---|---|---|---|
11/17/2022 | 355.58% | 康託·菲茨傑拉德 | → $20 | 開始承保 | →超重 |
09/15/2022 | 355.58% | 卡納科特·格納奇 | → $20 | 開始承保 | →購買 |
08/17/2022 | 127.79% | HC Wainwright公司 | $11 → $10 | 維護 | 買 |
01/31/2022 | 150.57% | HC Wainwright公司 | $10 → $11 | 升級 | 中性→購買 |
04/09/2021 | 127.79% | HC Wainwright公司 | $12 → $10 | 維護 | 中性 |
03/04/2021 | 173.35% | HC Wainwright公司 | $24 → $12 | 評級下調 | 購買→中性 |
01/25/2021 | 537.81% | 羅斯資本 | → $28 | 開始承保 | →購買 |
05/20/2020 | -65.83% | HC Wainwright公司 | $2.5 → $1.5 | 重申 | →購買 |
11/20/2019 | -43.05% | HC Wainwright公司 | $3 → $2.5 | 重申 | →購買 |
09/05/2019 | -76.08% | 羅斯資本 | $4.25 → $1.05 | 評級下調 | 購買→中性 |
06/19/2019 | -31.66% | HC Wainwright公司 | → $3 | 開始承保 | →購買 |
05/23/2018 | 287.24% | 詹尼·蒙哥馬利·斯科特 | → $17 | 開始承保 | →購買 |
02/26/2018 | 150.57% | 卡納科特·格納奇 | $7 → $11 | 維護 | 買 |
What is the target price for KemPharm (KMPH)?
肯德基(KemPharm)的目標價是多少?
The latest price target for KemPharm (NASDAQ: KMPH) was reported by Cantor Fitzgerald on November 17, 2022. The analyst firm set a price target for $20.00 expecting KMPH to rise to within 12 months (a possible 355.58% upside). 4 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2022年11月17日報道了肯德基(納斯達克:Kmph)的最新目標價。這家分析公司將目標價定為20美元,預計KMPH將在12個月內上漲至(可能上漲355.58%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for KemPharm (KMPH)?
肯德基(KemPharm)的最新分析師評級是多少?
The latest analyst rating for KemPharm (NASDAQ: KMPH) was provided by Cantor Fitzgerald, and KemPharm initiated their overweight rating.
肯德基(納斯達克代碼:KMPH)的最新分析師評級是由坎託·菲茨傑拉德提供的,肯德姆啟動了他們的增持評級。
When is the next analyst rating going to be posted or updated for KemPharm (KMPH)?
肯德基的下一次分析師評級將於何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KemPharm, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KemPharm was filed on November 17, 2022 so you should expect the next rating to be made available sometime around November 17, 2023.
分析師在進行了廣泛的研究後得出了股票評級,其中包括查閲公共財務報表,與肯德基的高管和客户交談,以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。KemPharm的上一次評級是在2022年11月17日提交的,所以你應該預計下一次評級將在2023年11月17日左右的某個時候公佈。
Is the Analyst Rating KemPharm (KMPH) correct?
分析師對肯德基(KemPharm)的評級正確嗎?
While ratings are subjective and will change, the latest KemPharm (KMPH) rating was a initiated with a price target of $0.00 to $20.00. The current price KemPharm (KMPH) is trading at is $4.39, which is within the analyst's predicted range.
雖然評級是主觀的,而且會發生變化,但最新的KemPharm(KMPH)評級是以0.00美元至20.00美元的目標價啟動的。肯德基目前的股價為4.39美元,在分析師的預測範圍內。